Sign in to our library of over $5 million worth of researchclose

Two Quick Steps

* Required Fields

Click Your Industry



Registered Customers

If you have an account with us, please log in.

* Required Fields



Subscribe today
Sign in to our library of over $5 million worth of researchclose

Two Quick Steps

* Required Fields

Click Your Industry



Registered Customers

If you have an account with us, please log in.

* Required Fields



Subscribe today

We deliver Mobile Wallet Market Research and SWOT Analysis from Alternative Energy to Pharmaceuticals and Healthcare Market Research Reports to Digital Media.

Skip to Main Content »

Search Site
Researchers Currently Online:2159

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals, April 2011


Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals, April 2011

Double click on above image to view full picture

Zoom Out
Zoom In
Additional Information
Price $1,000.00
Meta Description No
Publisher GlobalData
Date of Report Dec 4, 2011
Quick Overview
Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals, April 2011

Summary

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals, April 2011” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in March 2011. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.
Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

- Analysis of the market trends for the pharmaceutical industry in the global arena.
- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
- Analysis of partnership and licensing deals based on clinical stage of development of products.
- Summary of the pharmaceutical deals globally in the last six months.
- Information on the top deals happened in the pharmaceutical industry.
- Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

- Enhance your decision making capability in a more rapid and time sensitive manner.
- Find out the major deal performing segments for investments in your industry.
- Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
- Identify companies that are aggressively looking to raise capital in the market
- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
- Identify growth segments and opportunities in each region within the industry.
- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.
Table of Contents
1 Table of contents
1 Table of contents 2
1.1 List of Tables 4
1.2 List of Figures 6
2 Pharmaceuticals & Healthcare, Global, Deal Summary, 8
2.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, March 2011 8
2.2 Pharmaceuticals & Healthcare, Global, Top Deals, March 2011 10
2.2.1 Sanofi Completes Public Offering Of Notes For $7 Billion 10
2.2.2 Cephalon Receives Proposal For Acquisition By Valeant Pharmaceuticals 10
2.2.3 Terumo To Acquire CaridianBCT From Gambro 10
2.2.4 Valeant Pharmaceuticals International Completes Private Placement Of Notes For $1.5 Billion 10
2.2.5 Quest Diagnostics Announces Public Offering Of Senior Notes For $1.25 Billion 11
2.3 Pharmaceuticals and Healthcare, Global, by Type, Number of Deals and Deal Values, March 2011 12
3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 13
3.1 Pharmaceuticals and Healthcare, Global, M&A, March 2011 13
3.1.1 Top M&A Deals in March 2011 14
3.1.2 Pharmaceuticals and Healthcare, Global M&A Deals by Therapy Area, October 2010 – March 2011 15
3.2 Pharmaceuticals and Healthcare, Global, Equity Offering Deals, March 2011 16
3.2.1 Top Equity Offering Deals in March 2011 17
3.2.2 Pharmaceuticals and Healthcare, Global, Equity Offering Deals by Therapy Area, October 2010 – March 2011 18
3.3 Pharmaceuticals and Healthcare, Global, Debt Offering Deals, March 2011 19
3.3.1 Top Debt Offering Deals in March 2011 20
3.3.2 Pharmaceuticals and Healthcare, Global, Debt Offering Deals, by Therapy Area, October 2010 – March 2011 21
3.4 Pharmaceuticals and Healthcare, Global, Private Equity and Venture Capital Deals, March 2011 22
3.4.1 Top PE/VC Deals in March 2011 23
3.4.2 Pharmaceuticals and Healthcare, Global, PE/VC by Therapy Area, March 2011 24
3.4.3 Pharmaceuticals and Healthcare, Global, Venture Capital Deals by Stage of Financing, March 2011 25
3.4.4 Pharmaceuticals and Healthcare, Global, Top Venture Financing Firms, October 2010 – March 2011 26
3.4.5 Pharmaceuticals and Healthcare, Global, Top VC Backed Companies, October 2010 – March 2011 27
4 Pharmaceuticals and Healthcare, Global, Partnership Deals, March 2011 28
4.1 Pharmaceuticals and Healthcare, Global, Partnership Deals, March 2011 28
4.2 Pharmaceuticals and Healthcare, Global, Partnership Deals by Therapy Area, October 2010 – March 2011 29
4.3 Pharmaceuticals and Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), March 2011 30
4.3.1 Pharmaceuticals and Healthcare, Global, Top Partnership Deals by Payment Mode, March 2011 30
4.4 Pharmaceuticals and Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), October 2010 – March 2011 31
4.5 Pharmaceuticals and Healthcare, Global, Partnership Deals by Phase, Number Of Deals and Deal Values (US$ m), October 2010 – March 2011 32
4.6 Pharmaceuticals and Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), October 2010 – March 2011 33
5 Pharmaceuticals and Healthcare, Global, Licensing Agreements, March 2011 34
5.1 Pharmaceuticals and Healthcare, Global, Licensing Agreements, March 2011 34
5.2 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), March 2011 35
5.2.1 Pharmaceuticals and Healthcare, Global, Top Licensing Agreements by Deal Value, March 2011 36
5.2.2 Pharmaceuticals and Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, March 2011 36
5.2.3 Pharmaceuticals and Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, March 2011 37
5.3 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal values (US$ m), October 2010 – March 2011 38
5.4 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), October 2010 – March 2011 39
5.5 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), October 2010 – March 2011 40
5.6 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), October 2010 – March 2011 41
6 Deal Summary by Therapy Area 42
6.1 Pharmaceuticals and Healthcare, Global, Oncology Deals, March 2011 42
6.1.1 Oncology – Deals of the Month 43
6.2 Pharmaceuticals and Healthcare, Global, Central Nervous System Deals, March 2011 44
6.2.1 Central Nervous System – Deals of the Month 45
6.3 Pharmaceuticals and Healthcare, Global, Immunology Deals, March 2011 46
6.3.1 Immunology – Deals of the Month 47
6.4 Pharmaceuticals and Healthcare, Global, Infectious Disease Deals, March 2011 48
6.4.1 Infectious Diseases – Deals of the Month 49
6.5 Pharmaceuticals and Healthcare, Global, Metabolic Disorders, Deals, March 2011 50
6.5.1 Metabolic Disorders – Deals of the Month 51
6.6 Pharmaceuticals and Healthcare, Global, Cardiovascular Deals, March 2011 52
6.6.1 Cardiovascular – Deals of the Month 53
6.7 Pharmaceuticals and Healthcare, Global, Respiratory Deals, March 2011 54
6.7.1 Respiratory – Deals of the Month 55
7 Deal Summary by Geography 56
7.1 Pharmaceuticals and Healthcare, North America Deals, March 2011 56
7.1.1 North America – Deals of the Month 57
7.2 Pharmaceuticals and Healthcare, Europe, Deals, March 2011 58
7.2.1 Europe – Deals of the Month 59
7.3 Pharmaceuticals and Healthcare, Asia-Pacific, Regional Deals, March 2011 60
7.3.1 Asia-Pacific – Deals of the Month 61
7.4 Pharmaceuticals and Healthcare, Rest of the World, Deals, March 2011 62
7.4.1 Rest of the World – Deals of the Month 63
8 Pharmaceuticals and Healthcare, Top Advisors 64
8.1 Pharmaceuticals and Healthcare, Global, Top Financial Advisors, M&A, October 2010 – March 2011 64
8.2 Pharmaceuticals and Healthcare, Global, Top Financial Advisors, Equity Offerings, October 2010 – March 2011 65
9 Further Information 66
9.1 Methodology 66
9.2 About GlobalData 66
9.3 Contact Us 67
9.4 Disclosure information 67
9.5 Disclaimer 67




...